LOS GATOS, Calif. — KDx Diagnostics, a pioneering medical device company known for its innovative noninvasive urine test for bladder cancer, the URO17Ò test, is thrilled to announce strategic partnerships with leading distributors in Europe. These partnerships mark a significant milestone for KDx as we continue our mission to make...
treatment News
FORT LEE, N.J. – Kedrion Biopharma Inc., an international biopharmaceutical company specializing in the research and development, production, and commercialization of plasma-derived therapeutic products used in treating rare and serious diseases, announced today that plasminogen deficiency type 1 (PLGD-1) patients in the U.S. now have access to RYPLAZIM® (plasminogen, human-tvmh)....
FORT LEE, N.J. — Kedrion Biopharma announced today that it has received FDA approval for QIVIGY immune globulin intravenous (human)-kthm 10% liquid, indicated for treatment of adults with primary humoral immunodeficiency (PI)—a serious and often underdiagnosed group of disorders that compromise the immune system’s ability to function effectively. QIVIGY, a 10% IVIG...
FORT LEE, N.J. — Kedrion is proud to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to investigational treatment for Congenital Aceruloplasminemia, a rare genetic disorder affecting iron metabolism. This designation marks a significant milestone in Kedrion’s commitment to addressing the unmet medical needs of patients living with ultra-rare...
BALTIMORE, Maryland — Researchers at Kennedy Krieger Institute are sharing their expertise on autism spectrum disorder in a medical journal reaching thousands of pediatric professionals worldwide. The journal, Pediatric Clinics, provides the latest clinical information on health and related issues for children and adolescents. The newly released volume is titled...
LEXINGTON, Mass. — Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins, today announced the U.S. Food and...
LEXINGTON, Mass. — Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins, today announced that the U.S. Food and...
NEW YORK — Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data on the clinical activity of KRX-0401 (perifosine), the Company’s Akt-inhibitor for cancer, as a treatment for advanced renal cell carcinoma. Abstract #5034, entitled, “Phase II study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx)...
East Hanover, NJ – Researchers at Kessler Foundation have published a new clinical protocol examining the combination of aerobic exercise and cognitive rehabilitation to improve learning and memory in individuals with multiple sclerosis (MS) who have mobility disability. The article, “Rationale and methodology for examining the combination of aerobic exercise...
CHENGDU, China — Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof. Jun Shi’s research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) has recently published a research report titled “BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR...